|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
The FLT3 receptor tyrosine kinase plays an integral role in hematopoiesis, and one third of AML diagnoses exhibit gain-of-function mutations in FLT3, with the juxtamembrane domain internal tandem duplication (ITD) and the kinase domain D835Y variants observed most frequently.
|
30541869 |
2019 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
Retroviral expression of FLT3-N676K in myeloid 32D cells induced AML in syngeneic C3H/HeJ mice (n = 11/13, median latency 58 days), with a transforming activity similar to FLT3-internal tandem duplication (ITD) (n = 8/8), FLT3-TKD D835Y (n = 8/9), and FLT3-ITD-N676K (n = 9/9) mutations.
|
26891877 |
2016 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.
|
24046014 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
Our FLT3-Aurora kinase inhibitor, CCT137690, successfully inhibited growth of FLT3-ITD-D835Y cells in vitro and in vivo, suggesting that dual FLT3-Aurora inhibition may overcome selective FLT3 inhibitor resistance, in part due to inhibition of Aurora kinase, and may benefit patients with FLT3-mutated AML.
|
22354205 |
2012 |
|
Childhood Pre-B Acute Lymphoblastic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Three of these mutations were well-characterized common cALL mutations involved in constitutive activation of the mitogen-activated protein kinase pathway (FLT3 p.D835Y, NRAS p.G13D, BRAF p.G466A).
|
26345285 |
2015 |
|
leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.
|
18230792 |
2008 |
|
MYELODYSPLASTIC SYNDROME
|
|
0.010 |
GeneticVariation
|
BEFREE |
One patient had FLT3/TKD mutation (D835Y) at both MDS and AML stages.
|
14737077 |
2004 |
|
Childhood Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.
|
18230792 |
2008 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia.
|
22504183 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
|
23783394 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
|
22368270 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
|
22504184 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
|
22368270 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
|
23261068 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
|
20733134 |
2010 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Recurring mutations found by sequencing an acute myeloid leukemia genome.
|
19657110 |
2009 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
|
22368270 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
|
16857985 |
2006 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
MicroRNAs in liver disease.
|
22504185 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.
|
23321257 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
CausalMutation
|
CLINVAR |
In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.
|
24046014 |
2013 |